

# ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

NCT04363684

---

Status	RECRUITING
Sponsor	Mayo Clinic
Enrollment	2,100 participants

## Key Eligibility Criteria

---

### Inclusion (11)

- Familial FTLD (f-FTLD) participants (either is acceptable):
  - members of families in whom at least one member has a known disease-associated mutation in one of the major genes that cause f-FTLD: MAPT, GRN, C9orf72 (or other rare genes)
  - an autosomal dominant family history of a FTLD syndrome (without a known gene) verified by medical record review or well-documented family history including family members with a medical history consistent with FTLD or a related disorder.
- Sporadic FTLD (s-FTLD) participants:
  - Sporadic participants should be symptomatic with no known family history nor a genetic mutation indicating f-FTLD. All sporadic participants must have an FTLD syndrome as a referring diagnosis; those determined by ALLFTD clinicians to have non-FTLD diagnoses will be excluded from longitudinal visits, but their baseline visit will be included in comparative datasets. For inclusion in the longitudinal follow-up, participants should meet research criteria for one of the following FTLD syndromes:  
... and 6 more (see full listing online)

### Exclusion (6)

- Known presence of a structural brain lesion (e.g. tumor, cortical infarct) that could reasonably explain symptoms in a symptomatic participant.
- Known presence of an Alzheimer's disease causing mutation in PSEN1, PSEN2 or APP; or biomarker evidence for Alzheimer's disease as a cause of the clinical syndrome.
- A previous history of Korsakoff encephalopathy, severe alcohol dependence (within 5 years of onset of dementia), frequent alcohol or other substance intoxication, or other neurological disorder.
- Evidence through history or laboratory testing of uncorrected B12 deficiency (B12  $\lt$  95% of local laboratory's normal value), unregulated hypothyroidism (TSH  $\gt$  150% of normal), HIV positive, renal failure (creatinine  $\gt$  2), liver failure (ALT or AST  $\gt$  two times normal), respiratory failure that requires supplemental oxygen, large confluent white matter lesions, significant systemic medical illnesses such as deteriorating cardiovascular disease.
- Current medication likely to affect CNS functions in the opinion of the site PI.  
... and 1 more (see full listing online)

## Locations (27 total)

---

University of Alabama Birmingham, Birmingham, Alabama, United States  
University of California, Los Angeles, Los Angeles, California, United States  
University of California, San Diego, San Diego, California, United States  
... and 24 more locations

---

<https://clinicaltrials.gov/study/NCT04363684>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).